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and clinicallymore informative to compare new users of one
drug with new users of a comparison drug.4,5
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Insurance and Financial Concerns
Among Patients Seeking Care
for Acute Myocardial Infarction
To the Editor:Dr Smolderen and colleagues1 found that both
lack of insurance and concerns about costs among patients
with insurance were associatedwith delays in seeking emer-
gency care for acutemyocardial infarction (AMI). They also
found that an increased prehospital delaywas associatedwith
receiving less subsequent primary reperfusion therapy. Their
observations are consistent with the treatment-risk para-
dox: high-risk patients are the ones who are least likely to
access appropriate medical care.
There is a possible role of depression in their findings.
Depression is a prominent motivational factor for help-
seeking behavior and is associated not only with excess care
utilization but also with nonadherence to medical care and
reduced access to care. Globally, depression is one of the
leading disorders contributing to the overall burden of dis-
ease, and it is intertwined with coronary artery disease. De-
pression in MI patients is associated with an increased risk
of new cardiovascular events or death,2 low socioeconomic
status,3 reduced access to cardiac aftercare,4 and delays in
health care–seeking behavior.5
Depressed MI patients seem more likely to have no as-
surance andmore concerns about health care costs. It is con-
ceivable that depression results in inadequate health-
related help-seeking behavior, and in combinationwith poor
insurance status leads to suboptimal care.
Current options for depression treatment are only mod-
erately effective. It may be far better to detect high-risk pa-
tients early and to prevent depression by reducing wealth
inequalities on a national level and promoting access to care
for the most vulnerable.
Jerry van Riezen, MD
j.van.riezen@med.umcg.nl
Peter de Jonge, PhD
Interdisciplinary Center for Psychiatric Epidemiology
University Medical Center Groningen
Groningen, the Netherlands
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In Reply: In contrast to the assertion of Drs van Riezen and
de Jonge of a treatment-risk paradox in our findings, we
would note that the treatment-risk paradox refers to a pat-
tern inwhich physicians paradoxically apply therapies to pa-
tients with the least potential to benefit and less often ap-
ply therapies to those with themost opportunity to benefit.1
Instead, we have documented a patient behavior associated
with insurance status and likelihood of presenting promptly
for care of an AMI. Our concern is the implication of in-
surance status and potential disparities in access to care.
We agree that it is important to examine whether poten-
tial psychosocial factors—such as depression—may con-
found the relationship between insurance status and pre-
hospital delay times in patients with AMI. Indeed, our study
found that uninsured patients and insured patients with fi-
nancial concerns about accessing care each had an inde-
pendent association with longer times to hospital presen-
tation, even after adjusting for depressive symptoms andother
important psychological and socioeconomic variables, such
as perceived stress, social support, marital status, educa-
tional level, and residential zip code income.
There is a need for increased awareness about the asso-
ciation of depression and cardiovascular disease.2 Accord-
ingly, the Figure in our article reported that patients with
moderate to severe depressive symptoms were more likely
to delay seeking care during AMI (adjusted odds ratio, 1.21;
95% confidence interval, 1.03-1.42). However, we did not
find that depression was an effect modifier of the relation-
ship between health insurance status and prehospital de-
lays (P for interaction=.27). Although van Riezen and de
Jonge have suggested that reducing wealth inequalities on
a national level would prevent depression, it remains un-
clear to us the extent to which depressive symptoms present
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in patients with AMI are caused by environmental vs bio-
logic factors.
We do believe our findings underscore important con-
sequences from inadequate health care insurance coverage
for the substantial number ofUS residents experiencingAMIs.
Whether evolving changes in health care coverage in the
United States are associated with reductions in our ob-
served disparitieswill be important to assess as these changes
take effect.
Kim G. Smolderen, PhD
Tilburg University
Tilburg, the Netherlands
John A. Spertus, MD, MPH
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Donor Policies for Stem Cell Transplantation
To the Editor: In their Commentary, Drs Godley and van
Besien1 wrote of the challenges to finding HLA-matched do-
nors for patients requiring hematopoietic stem cell (HSC)
transplantation, especially when seeking unrelated donors
in the National Marrow Donor Program (NMDP) registry,
and proposed novel scientific approaches to overcome this
challenge. However, one simple step toward improving the
chance of finding a matched donor—and potentially sav-
ing more lives—remains unmet.
According to its Web site,2 the NMDP appears to defer
to the requirements for blood donation of the US Food and
Drug Administration (FDA), whose policy states, “Menwho
have had sex with othermen [MSM], at any time since 1977
(the beginning of the AIDS epidemic in the United States)
are currently deferred as blood donors.”2,3 This lifelong ban
from blood donation is neither medically nor scientifically
supported and has been challenged by many leading au-
thorities,4 including theAmericanMedicalAssociation,whose
policy states that “a shift to a 5-year deferral policy for blood
donation from men who have sex with men (MSM) is sup-
portable.”5
Findingmatched blood donors is relatively simple; there-
fore, excludingMSM reduces the volume of available blood
products but not the likelihood of finding a certain blood
type. The stakes in marrow donation are much higher: ev-
ery individual who is precluded from donation may repre-
sent a patient’s only chance for an acceptable HLA match.
Given the relatively low number of healthy individuals who
have joined the NMDP, the inclusion of MSM could have a
significant effect.
At a minimum, MSM could be allowed to join the regis-
trywith their risk noted. If they turn out to be the onlymatch
for a patient requiring HSC transplantation, that risk could
then be evaluated against the potential benefit by the indi-
vidual patient and his or her medical team.
I believe that the FDA should modify its policies, or the
NMDP should develop its own policies that take into ac-
count the special challenges faced by those seeking a stem
cell donor.
Douglas Hirsch Tischler, MA
dougtischler@gmail.com
New York, New York
Financial Disclosures: None reported.
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In Reply:Mr Tischler raises an important issue surrounding
the restrictions put forth by the NMDP for potential donors
of HSCs. Although the NMDP health history questionnaire
would seem to indicate linkage to the FDA policy on blood
transfusion, this is unfortunately misleading. When an indi-
vidual enters the NMDP system to register, one of the health
questions asked (ofmen only) is “ . . . In the past 5 years have
you had sex, even once with another male?” However, given
the sensitive techniques for detection of HIV and other trans-
mittable viruses, even this has become a controversial issue.
By their very nature, restrictions limit the HSC trans-
plant donor pool.1 The MSM restriction highlighted by
Tischler is one such limitation. Other viral diseases such as
hepatitis B and C also preclude someone from registering
to be a potential donor. In addition to exposure to viruses,
the NMDP excludes donors on the basis of age, only ac-
cepting donors 60 years and younger, althoughmany older
adults can collect sufficient numbers of HSCs to allow al-
logeneic stem cell transplantation.2
We agree with Tischler that when HLA-matched unre-
lated donors are limiting, there might be potential matched
donors who are excluded based on the current policies of the
NMDP.We support a tiered system inwhichpatients and their
treating physicians could learn of such potential donors who
would have been traditionally excluded if no other HLA-
matched donors were available and allow the patient and his
or her medical team the option to select such a donor. Un-
fortunately, such a change to the current system would not
help patients with rare HLA alleles, which was the subject of
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